AstraZeneca
AZN
1,507 hedge funds and large institutions have $196B invested in AstraZeneca in 2026 Q2 according to their latest regulatory filings, with 266 funds opening new positions, 525 increasing their positions, 495 reducing their positions, and 122 closing their positions.
118% more first-time investments, than exits
New positions opened: 266 | Existing positions closed: 122
29% more capital invested
Capital invested by funds: $152B → $196B (+$44.3B)
9% more funds holding
Funds holding: 1,385 → 1,507 (+122)
3.23% more ownership
Funds ownership: 48.84% → 52.06% (+3.2%)
6% more repeat investments, than reductions
Existing positions increased: 525 | Existing positions reduced: 495
17% less funds holding in top 10
Funds holding in top 10: 72 → 60 (-12)
42% less call options, than puts
Call options by funds: $704M | Put options by funds: $1.21B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$900M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$546M |
| 3 |
CCM
Causeway Capital Management
Los Angeles,
California
|
+$364M |
| 4 |
AAMU
AEGON Asset Management (UK)
Edinburgh,
United Kingdom
|
+$358M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$341M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$540M |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$318M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$257M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$241M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$229M |
AZN Hedge Fund Activity: Q2 2026 in Review
1,507 of the 8,345 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2026, worth a combined $196B — up 29% from $152B a quarter earlier.
Buyers outnumbered sellers: 266 funds opened new AZN positions and 122 closed out — a net gain of 144 holders — while 525 added to existing stakes and 495 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $900M. The largest seller was T. Rowe Price Associates, cutting an estimated $540M.
- 1,507 institutional investors held AstraZeneca (AZN) as of Q2 2026, up from 1,385 in Q1 2026.
- Funds reported $196B of AstraZeneca stock for Q2 2026, up 29% quarter-over-quarter.
- 266 funds opened new AstraZeneca positions in Q2 2026 and 122 closed out, a net change of +144 holders.
- The largest AstraZeneca buyer in Q2 2026 was Wellington Management Group, an estimated $900M added.
- The largest AstraZeneca seller in Q2 2026 was T. Rowe Price Associates, an estimated $540M sold.
Based on aggregated 13F filings for Q2 2026.